Triamcinolone
From Anvita Health Wiki
Contents |
Introduction
- Systemic agent: Tradenames: Aristocort, Kenacort, Kenalog.
- Topical: Tradenames: Aristocort, Kenalog, Kenalog in Orabase Nasal preparation: Tradename: Nasocort. Asthma medication: Tradename: Azmacort.
Indications
- anti-inflammatory agent ( systemic, topical)
- inhaled steroid for chronic suppression of inflammation associated with reactive airway disease
Contraindications
- Caution: Halogenated steroids should not be used on face
- pregnancy category = c
- pregnancy category = d
- safety in lactation = -
- safety in lactation = ?
- safety in lactation = ?
Dosage
- Tabs: 1, 2, 4, 8 mg
- Syrup: 4 mg/5 mL.
- Injection: Kenalog, Trivaris
- Cream: 0.025%, 0.1%, 0.5%.
- Ointment: 0.025% (15 & 80 g), 0.1% (15, 60, 240 g), 0.5% (15 g).
- Lotion: 0.025% (60 mL), 0.1% (15 mL, 60 mL). Paste 0.1% (Kenalog in Orabase)
- Medium potency (0.025%). Inhaler: 100 ug/spray (20 g)
Adverse-effects
- common (> 10%)
- less common (1-10%)
- uncommon (< 1%)
- seizures, mood swings, headache, skin atrophy, bruising, hyperpigmentation, acne, amenorrhea, Na+ & H20 retention, Cushing's syndrome, suppression of bone growth, abdominal distention, ulcerative esophagitis, pancreatitis, muscle wasting, hypersensitivity, delirium, hallucinations, euphoria
- short-term
- fluid & electrolyte disturbances
- hyperglycemia
- poor wound healing
- GI disturbances
- spread of infection
- long-term
- osteoporosis
- bone fractures
- pituitary adrenal axis insufficiency
- Cushing's syndrome
- acute adrenal insufficiency with rapid withdrawal of therapy
- skin atrophy
- hyperpigmentation
- Azmacort:
- dysphonia in 5-50% of patients, use of a spacer is of benefit
- oral candidiasis ( thrush)
- cough
- long-term use may result in loss of bone mineral density [7]
- Nasocort:
- irritation of nasal mucosa
- rarely nasal ulceration
- drug adverse effects of glucocorticoids
- drug adverse effects of immunosuppressive agents
Drug-interactions
Mechanism-of-action
- intermediate-acting glucocorticoids
- nasal preparation ( Nasocort)
- does NOT inhibit IgE synthesis or mast cell degranulation
- inhibits cytokine production, arachidonate metabolism, inflammation & mast cell proliferation
More General Terms
Internet Database
PubChem: 31307
PubChem: 5544
PubChem: 6216
PubChem: 6436
PubChem: 21826
PubChem: 62963
PubChem: 62964
PubChem: 633097
PubChem: 539244
PubChem: 16147
PubChem: 633091
PubChem: 5545
PubChem: 657338
References
- The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 85.
- Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
- Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 743
- Kaiser Permanente Northern California Regional Drug Formulary, 1998
- Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
- a) Journal Watch, Mass Med Soc 20(11):88 (June) 2000 b) Wong CA et al Lancet 355:1399, 2000 c) Sambrook PN Lancet 355:1385, 2000
